Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
Liquid biopsy developer Grail exemplifies 2020’s trend of sizeable mid-stage financings.
First-quarter venture investments barely register the pandemic - huge cash reserves should protect funding for biotech start-ups this year.
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.